Tranylcypromine Plus Amitriptyline for Electroconvulsive Therapy-Resistant Depression: A Long-Term Study

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Neuroscience

Background:

• Limited treatment options exist for electroconvulsive therapy-resistant major depressive disorder (ECT-r MDD).
• Combining monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) is a potential strategy for ECT-r MDD.
• The specific combination of amitriptyline (a TCA) and tranylcypromine (an MAOI) may offer tolerability benefits.

Purpose of the Study:

• To investigate the effectiveness and tolerability of combining amitriptyline and tranylcypromine in patients with ECT-r MDD.
• To assess the long-term maintenance effects of this combination therapy.

Main Methods:

• A retrospective cohort study of 31 patients diagnosed with ECT-r MDD.
• Open-label treatment with a combination of amitriptyline and tranylcypromine.
• Assessment of treatment response at 12 weeks and long-term follow-up.

Main Results:

• 80.6% of patients met response criteria within 12 weeks.
• Of the responders, 76% were followed for a mean of 9.37 years with no reported depressive episode recurrences.
• The combination was well-tolerated, with minor adverse effects but no severe events.

Conclusions:

• The combination of tranylcypromine and amitriptyline appears to be a safe and effective option for treating ECT-r MDD.
• This combination warrants further investigation for both acute treatment and long-term maintenance of ECT-r MDD.